TNNI3
MOLECULAR TARGETtroponin I3, cardiac type
TNNI3 (troponin I3, cardiac type) is targeted by 4 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting TNNI3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | hydroxyindoleacetic acid | 0.69 | 1 |
| 2 | Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as | 0.69 | 1 |
| 3 | Niridazole | 0.69 | 1 |
| 4 | Oxytetracycline | 0.69 | 1 |
About TNNI3 as a Drug Target
TNNI3 (troponin I3, cardiac type) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 4 compounds with documented TNNI3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
TNNI3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.